Stock comparison
CeriBell
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CBLL
CeriBell
Market cap
$712.18M
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CBLL | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 31F | 67B | HRMY |
| Benjamin Graham | 58D | 60C | HRMY |
| Philip Fisher | 58C | 75B | HRMY |
| Peter Lynch | 48D | 62C | HRMY |
| Joel Greenblatt | 4F | 28F | HRMY |
| Charlie Munger | 38D | 62C | HRMY |
| Terry Smith | 41D | 67B | HRMY |
Side-by-side metrics
| Metric | CBLL | HRMY |
|---|---|---|
| Market cap | $712.18M | $1.75B |
| P/E (TTM) | - | 11.8x |
| EV/EBIT | - | 6.4x |
| ROIC (TTM) | -39.83% | 12.5% |
| Gross margin | 87.72% | 76.55% |
| Net margin | -63.51% | 16.2% |
| Revenue CAGR 5y | 50.9% | 29.85% |
| EPS CAGR 5y | - | 46.45% |
| Debt / Equity | 0.2x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CBLL leads on
- P/E (TTM)-vs 11.8x+189%
- EV/EBIT-vs 6.4x+161%
- Revenue CAGR 5y50.9%vs 29.85%+41%
- Debt / Equity0.2xvs 0.2x+31%
HRMY leads on
- ROIC (TTM)12.5%vs -39.83%+131%
- Net margin16.2%vs -63.51%+126%
- Market cap$1.75Bvs $712.18M+59%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.